Congress Extends Rare Disease Vouchers and Boosts Pediatric Cancer Research
December 2 – December 2, 2025
Congress passed legislation extending rare pediatric disease drug vouchers and expanding FDA authority to mandate cancer studies for children. The package also secures $1.2 billion for Medicare improvements, signaling a major push for specialized medical research and funding.
Policies— 3 policys
Congress Passes Bill to Boost Pediatric Cancer Research and Extend Rare Disease Incentives
H.R. 1262
Congress expands FDA power to require pediatric cancer drug studies; extends rare pediatric drug voucher to 2030
S. 3302
Congress aims to expand FDA-required pediatric cancer drug studies and extend rare disease review vouchers
S. 932
Analysis generated by AI. Always verify with official sources.